Biogen stock trades near its 52-week high on growth bets

Biogen stock was trading at USD 228 on Nasdaq on September 24, 2026 at 3:10 p.m. ET, just 0.52 percent below its 52-week high of USD 229.19. The valuation puts the biotechnology company at a market capitalization of USD 33.69 billion while investors weigh fresh growth signals against pressure on established medicines.

Quarterly revenue beats expectations

Biogen generated USD 2.74 billion in second-quarter 2026 revenue, up 3.4 percent from the same quarter a year earlier and above the USD 2.46 billion consensus estimate. The result also exceeded the prior-year quarter's USD 5.47 adjusted EPS benchmark on revenue growth, although earnings were affected by deal-related costs and research spending.

Adjusted EPS reached USD 3.60 in Q2/2026, beating the USD 2.94 consensus by USD 0.66, according to MarketBeat. The comparison matters because the revenue beat came alongside a 34 percent year-over-year decline in adjusted earnings, highlighting the cost of Biogen's portfolio expansion.

New launches carry the growth case

Management's second-quarter update described core pharmaceutical revenue of USD 1.8 billion, up 4 percent year over year, while the growth portfolio exceeded USD 1 billion and grew 24 percent. That mix gives investors a measurable counterweight to declining legacy multiple sclerosis products.

Biogen's fiscal 2026 adjusted EPS guidance is USD 12.00 to USD 13.00. The company also scheduled its third-quarter results for October 28, 2026, before the market opens, according to Biogen.

Stock stays near the yearly high

At USD 228, Biogen stock was 0.52 percent below the USD 229.19 52-week high on September 24, 2026. The daily change was positive at 0.21 percent, leaving the next earnings release as the clearest scheduled checkpoint for the revenue and launch strategy.